DK0936912T3 - Inhibitorer af cysteinprotease - Google Patents

Inhibitorer af cysteinprotease

Info

Publication number
DK0936912T3
DK0936912T3 DK97937146T DK97937146T DK0936912T3 DK 0936912 T3 DK0936912 T3 DK 0936912T3 DK 97937146 T DK97937146 T DK 97937146T DK 97937146 T DK97937146 T DK 97937146T DK 0936912 T3 DK0936912 T3 DK 0936912T3
Authority
DK
Denmark
Prior art keywords
protease inhibitors
cysteine protease
cysteine
inhibitors
protease
Prior art date
Application number
DK97937146T
Other languages
Danish (da)
English (en)
Inventor
Robert W Marquis Jr
Daniel F Veber
Yu Ru
Castro Stephen Lo
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0936912T3 publication Critical patent/DK0936912T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
DK97937146T 1996-08-08 1997-08-07 Inhibitorer af cysteinprotease DK0936912T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2374296P 1996-08-08 1996-08-08
US4686797P 1997-05-08 1997-05-08
PCT/US1997/013875 WO1998005336A1 (en) 1996-08-08 1997-08-07 Inhibitors of cysteine protease

Publications (1)

Publication Number Publication Date
DK0936912T3 true DK0936912T3 (da) 2004-06-07

Family

ID=26697548

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97937146T DK0936912T3 (da) 1996-08-08 1997-08-07 Inhibitorer af cysteinprotease

Country Status (35)

Country Link
EP (1) EP0936912B1 (cs)
JP (1) JP3948753B2 (cs)
KR (1) KR100508045B1 (cs)
CN (1) CN1171870C (cs)
AP (1) AP865A (cs)
AR (1) AR009020A1 (cs)
AT (1) ATE259352T1 (cs)
AU (1) AU721853B2 (cs)
BG (1) BG64412B1 (cs)
BR (1) BR9711044A (cs)
CA (1) CA2262668C (cs)
CY (1) CY2528B1 (cs)
CZ (1) CZ297294B6 (cs)
DE (1) DE69727586T2 (cs)
DK (1) DK0936912T3 (cs)
DZ (1) DZ2285A1 (cs)
EA (1) EA001937B1 (cs)
ES (1) ES2213831T3 (cs)
HU (1) HU222788B1 (cs)
ID (1) ID18001A (cs)
IL (1) IL128378A (cs)
MA (1) MA24298A1 (cs)
MY (1) MY116947A (cs)
NO (1) NO317182B1 (cs)
NZ (1) NZ333987A (cs)
OA (1) OA10972A (cs)
PE (1) PE99198A1 (cs)
PL (1) PL191779B1 (cs)
PT (1) PT936912E (cs)
RO (1) RO120407B1 (cs)
SK (1) SK285127B6 (cs)
TR (1) TR199900249T2 (cs)
TW (1) TW542825B (cs)
UY (2) UY24660A1 (cs)
WO (1) WO1998005336A1 (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900964A3 (en) * 1995-10-30 2001-02-28 Smithkline Beecham Corp Protease inhibitors and pharmaceutical compositions containing these compounds
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
US6566373B2 (en) * 1997-05-06 2003-05-20 Smithkline Beecham Corporation Protease inhibitors
MA26494A1 (fr) * 1997-05-08 2004-12-20 Smithkline Beecham Corp Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1999021845A2 (en) 1997-10-27 1999-05-06 Agouron Pharmaceuticals, Inc. 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
MA26618A1 (fr) * 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
CO5180541A1 (es) * 1998-12-23 2002-07-30 Smithkline Beechman Corp Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
EP1384713B1 (en) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-amino-azepan-3-one derivatives as protease inhibitors
AU2003261482B2 (en) * 1998-12-23 2007-01-25 Smithkline Beecham Corporation Protease inhibitors
HUP0104768A3 (en) * 1998-12-23 2002-05-28 Smithkline Beecham Corp 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
WO2001034566A2 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
AU1474601A (en) * 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
EP1229912A4 (en) * 1999-11-10 2003-05-07 Smithkline Beecham Corp PROTEASE INHIBITORS
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
JP2003513956A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
WO2001034157A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034153A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
EP1229915A4 (en) * 1999-11-10 2003-05-14 Smithkline Beecham Corp PROTEASE INHIBITORS
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
BR0109356A (pt) 2000-03-21 2003-06-03 Smithkline Beecham Corp Inibidores de protease
CO5280088A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
BR0111693A (pt) * 2000-06-14 2004-04-06 Smithkline Beecham Corp Inibidores de protease
JP2004509083A (ja) * 2000-09-01 2004-03-25 スミスクライン・ビーチャム・コーポレイション 治療方法
CA2423315A1 (en) * 2000-09-25 2002-03-28 Solange Meyer Substituted amino-aza-cycloalkanes useful against malaria
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7132449B2 (en) * 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
EP1358176A2 (en) 2001-01-17 2003-11-05 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
EP1362052B1 (en) 2001-01-17 2007-03-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
CN100567293C (zh) 2001-02-23 2009-12-09 麦克公司 N-取代的非芳基-杂环nmda/nr2b拮抗剂
US6538017B2 (en) 2001-03-09 2003-03-25 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
US6710061B2 (en) 2001-03-09 2004-03-23 Ortho-Mcneil Pharamceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
WO2002080928A1 (en) 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2005504078A (ja) 2001-09-14 2005-02-10 アベンティス・ファーマスーティカルズ・インコーポレイテツド カテプシン阻害剤としての新規化合物および組成物
RU2004117877A (ru) 2001-11-14 2006-01-10 Авентис Фармасьютикалз Инк. (Us) Олигопептиды и композиции, содержащие их, в качестве ингибиторов катепсина s
EP1465862A1 (en) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
NZ534583A (en) * 2002-03-05 2006-11-30 Axys Pharm Inc Leucinamide derivatives suitable as cathepsin cysteine protease inhibitors
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
CN100368018C (zh) * 2005-05-26 2008-02-13 福建医科大学 蛇毒半胱氨酸蛋白酶抑制剂抗肿瘤侵袭与转移作用及应用
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4994471A (en) * 1989-05-12 1991-02-19 Boc, Inc. N-aryl-N-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds
US5216168A (en) * 1992-04-01 1993-06-01 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5206251A (en) * 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
US5585387A (en) * 1994-10-07 1996-12-17 Torcan Chemical Ltd. Prepration of cisapride
HUP9900964A3 (en) * 1995-10-30 2001-02-28 Smithkline Beecham Corp Protease inhibitors and pharmaceutical compositions containing these compounds

Also Published As

Publication number Publication date
CY2528B1 (en) 2006-04-12
MA24298A1 (fr) 1998-04-01
CA2262668C (en) 2006-05-09
SK285127B6 (sk) 2006-06-01
CN1171870C (zh) 2004-10-20
CZ297294B6 (cs) 2006-11-15
UY24863A1 (es) 2001-07-31
PL331533A1 (en) 1999-07-19
AR009020A1 (es) 2000-03-08
NZ333987A (en) 2000-09-29
AU3972697A (en) 1998-02-25
DE69727586D1 (en) 2004-03-18
RO120407B1 (ro) 2006-01-30
IL128378A (en) 2003-10-31
ID18001A (id) 1998-02-19
KR100508045B1 (ko) 2005-08-17
AP865A (en) 2000-08-17
BR9711044A (pt) 2000-10-24
TR199900249T2 (xx) 1999-04-21
HUP9902409A3 (en) 2000-06-28
TW542825B (en) 2003-07-21
OA10972A (en) 2003-03-04
PT936912E (pt) 2004-06-30
EP0936912A4 (en) 1999-10-13
JP2000516920A (ja) 2000-12-19
AU721853B2 (en) 2000-07-13
IL128378A0 (en) 2000-01-31
PL191779B1 (pl) 2006-07-31
DE69727586T2 (de) 2004-12-16
DZ2285A1 (fr) 2002-12-25
EP0936912B1 (en) 2004-02-11
BG103144A (en) 1999-09-30
HU222788B1 (hu) 2003-10-28
UY24660A1 (es) 1998-02-03
CN1232399A (zh) 1999-10-20
NO990548D0 (no) 1999-02-05
SK16299A3 (en) 1999-12-10
KR20000029863A (ko) 2000-05-25
JP3948753B2 (ja) 2007-07-25
NO317182B1 (no) 2004-09-06
BG64412B1 (bg) 2005-01-31
CZ36299A3 (cs) 1999-07-14
PE99198A1 (es) 1999-03-07
ATE259352T1 (de) 2004-02-15
HUP9902409A2 (hu) 1999-11-29
AP9701054A0 (en) 1997-10-31
NO990548L (no) 1999-04-07
EA199900186A1 (ru) 2000-04-24
EP0936912A1 (en) 1999-08-25
HK1022096A1 (en) 2000-07-28
WO1998005336A1 (en) 1998-02-12
MY116947A (en) 2004-04-30
EA001937B1 (ru) 2001-10-22
ES2213831T3 (es) 2004-09-01
CA2262668A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
DK0936912T3 (da) Inhibitorer af cysteinprotease
NO20012980D0 (no) Proteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
NO992734D0 (no) Serin-protease inhibitorer
NO975742D0 (no) Reversible cysteinproteasehemmere
NO20006718D0 (no) Proteaseinhibitorer
DE69823178D1 (de) Serine protease inhibitoren
ATE430158T1 (de) Hepatitis c tripeptide inhibitoren
NO990759L (no) Heterocykliske metallproteaseinhibitorer
NO983688D0 (no) Serin-protease-inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
NO995435D0 (no) Protease-inhibitorer
ID29885A (id) Penghambat serina protease
NO995434D0 (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO990856D0 (no) Spirosykliske metallprotease-inhibitorer
ATE277074T1 (de) Serine-protease-inhibitoren
DE69714222D1 (de) Serine-protease-inhibitoren
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO20011388L (no) Hydroksamat-inneholdende cystein- og serinproteasehemmere
MA26429A1 (fr) Inhibiteurs de protease
EE04114B1 (et) HIV-proteaasi inhibiitorid